BACKGROUND: Coagulation factor XI (FXI) inhibitors are a promising and novel class of anticoagulants, but a recent animal study found that FXI inhibition exacerbated diastolic dysfunction and heart ...
BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart ...
The ability to characterize the pulmonary circulation more fully paved the way for many advances. In the 1950s, Dr David ...
View all available purchase options and get full access to this article.
Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX (F.R.G., J.D.B., A.K., A.M.S., J.A.d.L.) Division of Cardiology, University of ...
View all available purchase options and get full access to this article.
Background: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are ...
Introduction: Aspirin (ASA) hypersensitivity is a challenge in determining the appropriate, cost-effective therapy in patients after percutaneous coronary intervention (PCI). Various ASA ...
BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...
Codeveloped by the American Heart Association and the American Red Cross, these guidelines represent the first comprehensive ...
BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback